中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2013年
35期
29-30
,共2页
拉米夫定%干扰素%慢性乙型肝炎%疗效分析
拉米伕定%榦擾素%慢性乙型肝炎%療效分析
랍미부정%간우소%만성을형간염%료효분석
Lamivudine%Interferon%Chronic hepatitis B%Analysis of curative effect
目的：探讨拉米夫定联合干扰素序贯治疗慢性乙型肝炎临床疗效。方法100例慢性乙型肝炎患者随机分为联合组(拉米夫定联合干扰素)和拉米夫定组,每组各40例。结果 HBVDNA阴转率两组均为100%；HBeAg血清转换率联合组为82%、拉米夫定组为44%；HBeAg阴转率联合组为84%、拉米夫定组为42%；ALT复常率联合组为100%、拉米夫定组为94%。结论拉米夫定联合干扰素的治疗可诱导包括抗-HB,血清学转换的持续应答,能迅速控制病毒血症,降低拉米夫定的耐药性的发生,有效改善患者肝功能,提高临床疗效,值得临床推广。
目的：探討拉米伕定聯閤榦擾素序貫治療慢性乙型肝炎臨床療效。方法100例慢性乙型肝炎患者隨機分為聯閤組(拉米伕定聯閤榦擾素)和拉米伕定組,每組各40例。結果 HBVDNA陰轉率兩組均為100%；HBeAg血清轉換率聯閤組為82%、拉米伕定組為44%；HBeAg陰轉率聯閤組為84%、拉米伕定組為42%；ALT複常率聯閤組為100%、拉米伕定組為94%。結論拉米伕定聯閤榦擾素的治療可誘導包括抗-HB,血清學轉換的持續應答,能迅速控製病毒血癥,降低拉米伕定的耐藥性的髮生,有效改善患者肝功能,提高臨床療效,值得臨床推廣。
목적：탐토랍미부정연합간우소서관치료만성을형간염림상료효。방법100례만성을형간염환자수궤분위연합조(랍미부정연합간우소)화랍미부정조,매조각40례。결과 HBVDNA음전솔량조균위100%；HBeAg혈청전환솔연합조위82%、랍미부정조위44%；HBeAg음전솔연합조위84%、랍미부정조위42%；ALT복상솔연합조위100%、랍미부정조위94%。결론랍미부정연합간우소적치료가유도포괄항-HB,혈청학전환적지속응답,능신속공제병독혈증,강저랍미부정적내약성적발생,유효개선환자간공능,제고림상료효,치득림상추엄。
Objective To investigate the clinical efficacy of lamivudine and interferon sequential therapy for treatment of chronic hepatitis B. Methods 100 cases of patients with chronic hepatitis B were randomly divided into combined group (combination of lamivudine and interferon and lamivudine group), each group had 40 cases. Results Negative rate of HBVDNA in two groups was 100%;HBeAg seroconversion rate was 82%in the combination group, lamivudine group was 44%;the negative rate of HBeAg was 84%in the combination group, lamivudine group was 42%;the recovery rate of ALT was 100%in the combination group, lamivudine group 94%. Conclusion Treatment of lamivudine combined with interferon can induce anti-HB seroconversion, sustained response, can quickly control viremia, reduce the occurrence of lamivudine resistance, effectively improve the liver function of patients, improve the curative effect, so it is worth the clinical promotion.
